Cargando…
HER2 expression identifies dynamic functional states within circulating breast cancer cells
Circulating tumor cells (CTCs) in women with advanced estrogen receptor-positive/HER2-negative breast cancer acquire a HER2-positive subpopulation following multiple courses of therapy(1,2). In contrast to HER2-amplified primary breast cancer, which is highly sensitive to HER2-targeted therapy, the...
Autores principales: | Jordan, Nicole Vincent, Bardia, Aditya, Wittner, Ben S., Benes, Cyril, Ligorio, Matteo, Zheng, Yu, Yu, Min, Sundaresan, Tilak K., Licausi, Joseph A., Desai, Rushil, O’Keefe, Ryan M., Ebright, Richard Y., Boukhali, Myriam, Sil, Srinjoy, Onozato, Maristela L., Iafrate, Anthony J., Kapur, Ravi, Sgroi, Dennis, Ting, David T., Toner, Mehmet, Ramaswamy, Sridhar, Haas, Wilhelm, Maheswaran, Shyamala, Haber, Daniel A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5161614/ https://www.ncbi.nlm.nih.gov/pubmed/27556950 http://dx.doi.org/10.1038/nature19328 |
Ejemplares similares
-
A microfluidic device for label-free, physical capture of circulating tumor cell-clusters
por: Sarioglu, A. Fatih, et al.
Publicado: (2015) -
COX-2 mediates tumor-stromal prolactin signaling to initiate tumorigenesis
por: Zheng, Yu, et al.
Publicado: (2019) -
Dynamic Chromatin Modification Sustains Epithelial-Mesenchymal Transition following Inducible Expression of Snail-1
por: Javaid, Sarah, et al.
Publicado: (2013) -
Blood-based monitoring identifies acquired and targetable driver HER2 mutations in endocrine-resistant metastatic breast cancer
por: Medford, Arielle J., et al.
Publicado: (2019) -
Metastatic Breast Cancer With ESR1 Mutation: Clinical Management Considerations From the Molecular and Precision Medicine (MAP) Tumor Board at Massachusetts General Hospital
por: Bardia, Aditya, et al.
Publicado: (2016)